Pain
Neuropathic Pain
Neuropathic Pain is a pain condition. In this reference, it is the health concern being discussed, while Acetyl-L-Carnitine (ALCAR), CBD (Cannabidiol), Lavender Extract, and Saffron Extract are considered separately as possible interventions.
Neuropathic Pain is categorized as a pain condition. Explore its dedicated overview and related wellness information.
This list shows research findings, not treatments. Nothing here replaces medical care. If you have this condition, talk to a doctor.
What may help
None of these options has good evidence yet. Best evidence first.
1 option:1 not enough evidence
MeditationpracticeNot enough evidence
Too few or too small studies to know if it works.
The one study found a benefit.
Open the Meditation page
The expert view shows every study, dose protocol and source.
What may help
Interventions recorded as helping with this condition1 listedThe best we have, but the evidence is still weak
- →PracticesMeditationCertaintyLowSourceReview
86% of 22 studies reported significant pain reduction with CBT, mindfulness, and meditation-based interventions; effects consistent across diabetes (89%), cancer (83%), and SCI (80%) etiologies.
Open MeditationWho was studied
- People with a condition
What to avoid
Interventions recorded as making it worseNothing in this library is currently recorded as making Neuropathic Pain worse. Coverage is partial, and absence here is not evidence of safety.
How to read the evidence
Evidence tier — overall strength of the evidence for the whole compound
- StrongWell established — backed by strong, consistent human research.
- ModerateSome genuine support, but mostly from small or lower-quality studies. Promising, not proven.
- PreliminaryEarly-stage evidence — a promising hypothesis, not an established effect yet.
- LimitedVery limited evidence — treat this as a hypothesis, not proof.
- InsufficientNot enough good evidence to draw conclusions yet.
Certainty — how sure we can be that the effect is real
- Very highVery sure — strong, consistent evidence
- HighFairly sure — consistent evidence from good studies
- MediumModerately sure — new studies could change this
- LowNot sure — little or mixed evidence
- Very lowVery unsure — almost no usable evidence
Source — where the data comes from
- Meta-analysisPooled analysis of many trials — the strongest evidence
- RCTRandomized controlled trial — a strong human study design
- ClinicalA human clinical study
- Reference knowledgeFrom general health-science or pharmacology references, not a study of this exact claim
- Animal researchStudied in animals, not humans
- Community reportsAggregated user reports — anecdotal signal, not evidence
- TheoreticalMechanism-based reasoning, not yet tested
Study grade — quality of each underlying study (A best, D weakest)
- AHigh-quality — strong, consistent human trials
- BGood — solid evidence with some limitations
- CModerate — limited, small, or mixed-quality studies
- DWeak — preliminary, indirect, or animal-only
Confidence — how strongly the sources back a finding
A 0–100 score from study quality and agreement
Most supplement evidence is graded C–D. Read it as preliminary signal, not proof.
Full write-up
What is it
Neuropathic Pain is a pain condition. In this reference, it is the health concern being discussed, while Acetyl-L-Carnitine (ALCAR), CBD (Cannabidiol), Lavender Extract, and Saffron Extract are considered separately as possible interventions. Findings associated with these options do not define every person’s experience of Neuropathic Pain or establish that any one option will help.
Evidence-backed options
The evidence for these options is limited overall and does not establish a uniform response for neuropathic pain. Reported outcomes include changes in pain intensity, mood, and quality of life, with benefits appearing over relatively short study periods. The timing was not identical across approaches: one report described mood changes before later pain and quality-of-life findings, while another assessed pain outcomes after several weeks of use.
The evidence also applies to different forms of use, including oral preparations and inhalation, so findings from one approach should not automatically be extended to another. Saffron Extract is supported here only by a mouse model, making its relevance to people less certain than findings from human research. Clinical interpretation should therefore consider the type of evidence, the population studied, and the outcomes measured. Anyone considering an option for a medical condition should discuss it with a clinician.